Latest Period
Q2 2026
Security Snapshot
Rein Therapeutics, Inc. - Common Stock, $0.001 par value per share (RNTX) Institutional Ownership
CUSIP: 00887A204
13F Institutional Holders and Ownership History from Q4 2022 to Q2 2026
Institutions Reporting
59
Shares (Excl. Options)
40,841,277
Price
$1.04
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.001 par value per share
- Symbol
- RNTX on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 40,841,277
- Total 13F value
- $42,455,116
- Portfolio coverage rank
- 0%
- Share change
- +29,330,965
- Value change
- +$30,472,999
- Number of holders
- 59
- Shares outstanding
- 84,905,660
- SEC-reported price per share
- $0.99
- Insider filing price
- $0.99
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- RNTX - Rein Therapeutics, Inc. - Common Stock, $0.001 par value per share is tracked under CUSIP 00887A204.
- 59 institutions reported positions in Q2 2026.
- 8 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 45 to 59 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $14,839,714 to $42,455,116.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 59 institutions filings for Q2 2026.
Security key
00887A204
Latest holder period
Q2 2026
13F holders
59
13D/G owners
8
CIK / CUSIP context first
Open Q2 2026 holders
RNTX full holder history
Rein Therapeutics, Inc. SEC filings
Rein Therapeutics, Inc. company facts
Rein Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 00887A204:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
8
Security
RNTX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BIOS Fund I, LP | 10% | $10,136,753 | 7,797,502 | BIOS CAPITAL MANAGEMENT, LP | 06 May 2026 | |||
| Voss Capital, LP | 6.6% | -61% | $5,883,235 | +$1,235,508 | 5,656,957 | +27% | Voss Capital, LP | 30 Jun 2026 |
| Funicular Funds, LP | 6.7% | $6,753,500 | 5,195,000 | Funicular Funds, LP | 01 May 2026 | |||
| ADAR1 Capital Management, LLC | 5.3% | $4,455,000 | 4,500,000 | ADAR1 Capital Management, LLC | 30 Jun 2026 | |||
| Lynwood Capital Management Inc. | 5% | -18% | $4,237,695 | -$464,805 | 4,280,500 | -9.9% | Lynwood Capital Management Inc. | 30 Jun 2026 |
| LYTTON LAURENCE W | 4.9% | -15% | $4,196,242 | -$258,758 | 4,238,628 | -5.8% | LYTTON LAURENCE W | 30 Jun 2026 |
| BIOS Fund III, LP | 6.2% | $5,156,801 | 3,683,429 | BIOS EQUITY PARTNERS III, LP | 05 May 2025 | |||
| UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO | 4.4% | $1,758,017 | 960,665 | UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO | 04 Nov 2024 |
As of 30 Jun 2026, 59 institutional investors reported holding 40,841,277 shares of Rein Therapeutics, Inc. - Common Stock, $0.001 par value per share (RNTX). This represents 48% of the company’s total 84,905,660 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
46%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Voss Capital, LP | 6.2% | 5,261,921 | +20% | 0.27% | $5,472,398 |
| Cable Car Capital, LP | 6.1% | 5,195,000 | +1137% | 0.12% | $5,402,800 |
| ADAR1 Capital Management, LLC | 5.3% | 4,500,000 | 0.22% | $4,680,000 | |
| VANGUARD CAPITAL MANAGEMENT LLC | 4% | 3,377,910 | +238% | 0% | $3,513,026 |
| BIOS Capital Management, LP | 3.5% | 2,982,375 | +50% | 7.4% | $3,101,670 |
| Ikarian Capital, LLC | 3.5% | 2,950,000 | 0.51% | $3,068,000 | |
| GREAT POINT PARTNERS LLC | 3% | 2,575,000 | 0.63% | $2,678,000 | |
| CITADEL ADVISORS LLC | 2.9% | 2,438,711 | 0% | $2,536,259 | |
| Velan Capital Investment Management LP | 2% | 1,700,000 | 1.1% | $1,768,000 | |
| Senvest Management, LLC | 1.4% | 1,230,895 | +433% | 0.04% | $1,280,131 |
| Prosight Management, LP | 1.3% | 1,100,000 | +167% | 0.2% | $1,144,000 |
| Bleichroeder LP | 1.2% | 1,000,000 | 0.19% | $1,040,000 | |
| BOOTHBAY FUND MANAGEMENT, LLC | 1% | 889,450 | 0.02% | $925,028 | |
| GEODE CAPITAL MANAGEMENT, LLC | 0.86% | 733,139 | +113% | 0% | $762,540 |
| UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO | 0.6% | 511,610 | 0% | 0.06% | $532,074 |
| VANGUARD FIDUCIARY TRUST CO | 0.45% | 382,515 | +148% | 0% | $397,816 |
| STATE STREET CORP | 0.45% | 379,604 | +400% | 0% | $394,788 |
| Empery Asset Management, LP | 0.44% | 370,834 | 0.45% | $385,667 | |
| Sigma Planning Corp | 0.42% | 353,677 | +1.4% | 0.01% | $367,824 |
| BlackRock, Inc. | 0.38% | 326,204 | +376% | 0% | $339,253 |
| Texas Capital Bank Wealth Management Services Inc | 0.35% | 300,758 | +9.9% | 0.02% | $312,789 |
| Sequoia Financial Advisors, LLC | 0.29% | 250,000 | 0% | $260,000 | |
| GAGNON SECURITIES LLC | 0.27% | 229,070 | -4.4% | 0.05% | $238,233 |
| Stonepine Capital Management, LLC | 0.26% | 218,038 | 0.17% | $226,760 | |
| Palogic Value Management, L.P. | 0.21% | 180,000 | 0% | 0.07% | $187,200 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
15
Latest
Q2 2026
Rows shown
1-15 of 15
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 40,841,277 | $42,455,116 | +$30,472,999 | $1.04 | 59 |
| 2026 Q1 | 11,396,524 | $14,839,714 | +$855,214 | $1.30 | 45 |
| 2025 Q4 | 10,799,701 | $12,545,188 | +$2,685,239 | $1.16 | 46 |
| 2025 Q3 | 8,489,234 | $9,760,613 | +$2,095,461 | $1.14 | 39 |
| 2025 Q2 | 6,657,209 | $9,543,969 | +$863,809 | $1.40 | 35 |
| 2025 Q1 | 6,017,421 | $10,645,603 | +$584,856 | $1.77 | 37 |
| 2024 Q4 | 5,679,222 | $13,062,350 | -$2,786,804 | $2.30 | 30 |
| 2024 Q3 | 4,605,051 | $16,285,431 | -$1,010,220 | $3.54 | 29 |
| 2024 Q2 | 4,894,669 | $13,494,162 | +$5,623,418 | $2.77 | 27 |
| 2024 Q1 | 1,688,450 | $10,954,455 | +$3,910,201 | $6.63 | 22 |
| 2023 Q4 | 1,063,685 | $3,241,840 | +$183,775 | $3.05 | 19 |
| 2023 Q3 | 1,045,511 | $1,588,393 | +$34,111 | $1.52 | 15 |
| 2023 Q2 | 1,022,688 | $1,829,841 | -$43,089 | $1.79 | 16 |
| 2023 Q1 | 1,050,566 | $1,302,967 | -$651,889 | $1.24 | 17 |
| 2022 Q4 | 1,356,571 | $3,214,622 | +$3,214,622 | $2.37 | 16 |